BANK VONTOBEL/CALL/MODERNA/88/1/21.06.24 | Market Closed - Euronext Paris 10:00:00 03/06/2024 pm IST | ||
| 5.27 EUR | +3.74% |
|
| Current month | +6.30% | ||
| 1 month | +59.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 5.27 | +3.74% |
| 31/24/31 | 5.08 | -9.29% |
| 30/24/30 | 5.6 | +4.09% |
| 29/24/29 | 5.38 | -5.61% |
| 28/24/28 | 5.7 | -22.45% |
Real-time Euronext Paris
Last update June 03, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| KJ52V | |
| ISIN | DE000VM3U226 |
| Date issued | 19/10/2023 |
| Strike | 88 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 1 : 1 |
| Emission price | 1.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.6 € |
|---|---|
| Lowest since issue | 0.665 € |
| Spread | 0.02 € |
| Spread % | 0.38% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
142.6
USD
Average target price
142.8
USD
Spread / Average Target
+0.18%
- Stock Market
- Warrants
- KJ52V Warrant
